Cite

HARVARD Citation

    Frishberg, Y. et al. (2021). Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1. Clinical journal of the American Society of Nephrology. 16 (7), pp. 1025-1036. [Online]. 
  
Back to record